Inducible Co-Stimulator (ICOS) in transplantation: A review.

Autor: Hodgson R; Department of Surgery, University of Melbourne, Heidelberg, Australia; Division of Surgery, Northern Health, Epping, Australia. Electronic address: russell.hodgson@nh.org.au., Christiansen D; Department of Surgery, University of Melbourne, Heidelberg, Australia., Ierino F; Department of Surgery, University of Melbourne, Heidelberg, Australia; Department of Nephrology, St Vincent's Hospital, Fitzroy, Australia., Sandrin M; Department of Surgery, University of Melbourne, Heidelberg, Australia.
Jazyk: angličtina
Zdroj: Transplantation reviews (Orlando, Fla.) [Transplant Rev (Orlando)] 2022 Dec; Vol. 36 (4), pp. 100713. Date of Electronic Publication: 2022 Jul 09.
DOI: 10.1016/j.trre.2022.100713
Abstrakt: Prevention of T cell activation is one of the goals of successful organ and tissue transplantation. Blockade of T cell co-stimulation, particularly of the CD28:B7 interaction, has been shown to prolong graft survival. Inducible Co-Stimulator (ICOS) is the third member of the B7 family and here we review the literature on ICOS, its receptor (B7RP-1), and blockade of this pathway in transplant models. ICOS:B7RP-1 are a single receptor:ligand pair with a loss of function of either being implicated in some autoimmune diseases. ICOS has multiple functions, related to its constitutive expression on B cells and activated T cells. In in vitro transplant models, ICOS:B7RP-1 blockade has produced mixed results as to its ability to modulate lymphocyte proliferation. Several in vivo transplant models demonstrate varying degrees of success in prolonging graft survival. Timing and dose of treatment appear important, and combination with other immunosuppressive treatments may also be of benefit. As ICOS has multiple functions, it may be that the observed variable results are due to inadvertent inactivation of graft protective functions. If these barriers can be overcome, ICOS:B7RP-1 blockade could provide an important target for future immunosuppression regimens.
Competing Interests: Declaration of Competing Interest None.
(Copyright © 2022 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: